Effects of systematic treatment based on overnight simultaneous monitoring of electroencephalography and cystometry.
OBJECTIVE
To clarify the effects of systematic treatment based on overnight simultaneous monitoring by electroencephalography (EEG) and cystometry (CM) on each type of enuresis.


METHODS
For enuresis type I, the change in the awakening response during the conditioning treatment with a therapeutic machine was observed. For enuresis type IIa, the effect of imipramine on the EEG was observed. For enuresis type IIb, the effect of oxybutynin hydrochloride on the cystometrogram (CMG) was observed.


RESULTS
Values, in which the awakening score on the second night was subtracted from the score on the last night, were significantly higher in the effective cases than in the unchanged cases. Out of the 3 patients in whom imipramine was effective, an awakening response on the EEG was observed in 2. Neither of the 2 unchanged cases showed an awakening response. Out of 4 patients in whom oxybutynin hydrochloride was effective, uninhibited contractions (UIC) on the CMG disappeared in 3. UIC stopped in neither of the 2 unchanged cases.


CONCLUSIONS
Improvement of the awakening response plays an important role in the effectiveness of conditioning treatment with our therapeutic machine. The generation of awakening response is thought to be the most important result of imipramine directly concerned with its clinical effect on enuresis type IIa. The main result with oxybutynin hydrochloride in enuresis type IIb is thought to be related to its antispasmodic effect.
Kawauchi
A
A
Department of Urology, Kyoto Prefectural University of Medicine, Japan. kawauchi@koto.kpu-m.ac.jp
Imada
N
N
Tanaka
Y
Y
Yamao
Y
Y
Watanabe
H
H
D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D018680:Cholinergic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D003950:Diagnostic Techniques, Urological; D004569:Electroencephalography / Q000187:drug effects; D004775:Enuresis / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007099:Imipramine / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008333:Mandelic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D008991:Monitoring, Physiologic; D010276:Parasympatholytics / Q000008:administration & dosage / Q000627:therapeutic use*; D012890:Sleep / Q000187:drug effects; D014851:Wakefulness / Q000187:drug effects
D018759:Adrenergic Uptake Inhibitors; D018680:Cholinergic Antagonists; D008333:Mandelic Acids; D010276:Parasympatholytics; C005419:oxybutynin; D007099:Imipramine